公开(公告)号：US20250121048A1

公开(公告)日：2025-04-17

申请号：US18990184

申请日：2024-12-20

Applicant: BAYLOR RESEARCH INSTITUTE

Inventor： SangKon OH ,  Sandra ZURAWSKI ,  Gerard ZURAWSKI

IPC: A61K39/12 ,  A61K39/00 ,  A61K39/395 ,  C07K14/005 ,  C07K16/28 ,  C12N7/00

Abstract: Embodiments relate to novel vaccines against human papillomavirus (HPV) and HPV-related diseases, including multiple types of cancers. The HPV vaccines are composed of anti-human dendritic cell (DC) surface receptor antibodies, including CD40, and E6/7 proteins of HPV16 and 18. The technology described is not limited to making vaccines against HPV16- and HPV18-related diseases and can be applied to making vaccines carrying E6/7 from any type of HPV. The HPV vaccines described can target DCs, major and professional antigen presenting cells (APCs), and can induce and activate potent HPV E6/7-specific and strong CD4+ and CD8+ T cell responses. The HPV vaccines can be used for the prevention of HPV infection and HPV-related diseases as well as for the treatment of HPV-related diseases, including cancers.

公开(公告)号：US20250025548A1

公开(公告)日：2025-01-23

申请号：US18710734

申请日：2022-11-16

Applicant: Institut National de la Santé et de la Recherche Médicale ,  Assistance Publique - Hopitaux de Paris ,  Baylor Research Institute ,  Universite Paris Est Creteil Val De Marne

Inventor： Yves LEVY ,  Gérard ZURAWSKI ,  Sandra ZURAWSKI ,  Mireille CENTLIVRE ,  Christine LACABARATZ ,  Sylvain CARDINAUD ,  Mathieu SURENAUD

IPC: A61K39/215 ,  A61P31/14 ,  C07K16/28 ,  C12N7/00

Abstract: Sarbecoviruses (lineage B of genus Betacoronavirus) have caused two major outbreaks during the past two decades: SARS-CoV in 2003, and SARS-CoV-2 from 2019. SARS-CoV-2 vaccines will be essential to reduce morbidity and mortality. Therefore, universal vaccines against this class of viruses are key to ending the current pandemic, but also for preventing additional emergent variations and future outbreaks of SARS-like viruses that are continuously found from nature reservoirs. Now, the inventors produced an antibody that is directed against a surface antigen (i.e., CD40) of an antigen presenting cell (i.e., dendritic cell) wherein the heavy chain is conjugated or fused to a protein N polypeptide of SAR-CoV-2 and the light chain is fused to a RBD polypeptide. In particular, the inventors show that said antibody could elicit immune responses against Sarbecoviruses.

公开(公告)号：US12186379B2

公开(公告)日：2025-01-07

申请号：US17447607

申请日：2021-09-14

Applicant: BAYLOR RESEARCH INSTITUTE

Inventor： Sangkon Oh ,  Gerard Zurawski

IPC: A61K39/00 ,  A61P25/00 ,  A61P25/28 ,  A61P37/02 ,  C07K14/46 ,  C07K16/28

Abstract: Methods and compositions for treating multiple sclerosis using dendritic cell anti-ASGPR antibodies fused to myelin basic protein or myelin oligodendrocyte glycoprotein are provided.

公开(公告)号：US12016915B2

公开(公告)日：2024-06-25

申请号：US17454108

申请日：2021-11-09

Applicant: BAYLOR RESEARCH INSTITUTE

Inventor： SangKon Oh ,  Dapeng Li ,  Jacques Banchereau ,  Gerard Zurawski ,  Sandra Zurawski

IPC: A61K39/145 ,  A61K39/00 ,  A61K47/68 ,  A61K51/10 ,  C07K14/005 ,  C07K14/195 ,  C07K14/37 ,  C07K14/405 ,  C07K14/435 ,  C07K16/28 ,  C12N5/0784 ,  C12N7/00

CPC classification number: A61K39/145 ,  A61K47/6849 ,  A61K51/1027 ,  C07K14/005 ,  C07K14/195 ,  C07K14/37 ,  C07K14/405 ,  C07K14/435 ,  C07K16/28 ,  C12N5/0639 ,  C12N7/00 ,  A61K2039/5154 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/56 ,  C07K2317/74 ,  C07K2317/75 ,  C07K2317/92 ,  C12N2760/16122 ,  C12N2760/16134

Abstract: The present invention includes compositions and methods for making and using anti DC-ASGPR antibodies that can, e.g., activate DCs and other cells.

公开(公告)号：US11806390B2

公开(公告)日：2023-11-07

申请号：US17301704

申请日：2021-04-12

Applicant: BAYLOR RESEARCH INSTITUTE

Inventor： Gerard Zurawski ,  Jacques F. Banchereau ,  Anne-Laure Flamar ,  Peter Klucar ,  Keiko Akagawa ,  Sandra Zurawski ,  SangKon Oh

IPC: A61K39/00 ,  A61K39/385 ,  C07K14/005 ,  C07K16/00 ,  G01N33/68 ,  C07K16/28 ,  C07K14/435

CPC classification number: A61K39/001129 ,  A61K39/385 ,  C07K14/005 ,  C07K14/435 ,  C07K16/00 ,  C07K16/2878 ,  G01N33/6863 ,  A61K39/00 ,  A61K2039/6056 ,  A61K2039/627 ,  A61K2039/64 ,  C07K2317/41 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/74 ,  C07K2317/77 ,  C07K2317/80 ,  C07K2319/00 ,  C07K2319/30 ,  C07K2319/33 ,  C07K2319/40 ,  C07K2319/91 ,  C12N2740/16222 ,  C12N2740/16322 ,  C12N2760/16122 ,  C12N2770/24222 ,  C12N2770/24234 ,  Y02A50/30

Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.

公开(公告)号：US20230134568A1

公开(公告)日：2023-05-04

申请号：US17818276

申请日：2022-08-08

Applicant: BAYLOR RESEARCH INSTITUTE

Inventor： Jacques F. Banchereau ,  Maria Virginia Pascual

IPC: A61K38/20 ,  C07K16/24 ,  A61K38/17 ,  C07K14/545 ,  A61P19/02 ,  A61K39/395 ,  G01N33/68

Abstract: The present invention includes compositions and methods for treating arthritic joints found in patients with autoinflammation, e.g., systemic onset juvenile idiopathic arthritis, by administering at the site of inflammation a therapeutically effective amount of at least one agent that reduces or blocks the bioavailability of interleukin-1β.

公开(公告)号：US11618926B2

公开(公告)日：2023-04-04

申请号：US16489597

申请日：2018-02-28

Applicant: BAYLOR RESEARCH INSTITUTE

Inventor： Ajay Goel ,  Raju Kandimalla ,  Shusuke Toden ,  Roshni Roy ,  Tsuyoshi Ozawa ,  Takatoshi Matsuyama ,  Wenhao Weng

IPC: C12Q1/6886

Abstract: Dysregulated expression of microRNAs (miRNAs) has emerged as a hallmark feature in human cancers. Aspects of the disclosure relate to methods for selecting optimal therapy for a patient from several alternative treatment options. A major clinical challenge in cancer treatment is to identify the subset of patients who will benefit from a therapeutic regimen, both in metastatic and adjuvant settings. The number of anti-cancer drugs and multi-drug combinations has increased substantially in the past decade, however, treatments continue to be applied empirically using a trial-and-error approach. Here methods and compositions are provided to determine the optimal treatment option for cancer patients.

公开(公告)号：US11603566B2

公开(公告)日：2023-03-14

申请号：US16322380

申请日：2017-08-04

Applicant: BAYLOR RESEARCH INSTITUTE

Inventor： Ajay Goel ,  Jinsei Miyoshi

IPC: C12Q1/68 ,  C12Q1/6886 ,  A61P35/04 ,  A61K33/243 ,  A61K31/337 ,  A61K31/351 ,  A61K31/513 ,  C12Q1/02

Abstract: The current disclosure relates to therapeutic treatments and diagnostic methods for esophageal cancer based on the expression level of biomarker miRNAs. Aspects of the disclosure relate to a method of treating esophageal cancer (EC) in a patient, said method comprising: diagnosing the patient with esophageal cancer when the patient is determined to have an elevated or decreased level of expression of one or more miRNAs selected from mir-15b, miR-17, mir-18a, mir-21, mir-23a, mir-24-2, mir-25, mir-27a, mir-93, mir-103, mir-106b, mir-129-2, mir-139, mir-146b, mir-148a, mir-151, miR-155, mir-181a-1, mir-181a, mir-181b-1, mir-181b, mir-182, mir-183, mir-192, mir-194-1, mir-194-2, mir-196a-1, mir-196a-2, mir-196b, mir-205, mir-215, mir-223, mir-224, mir-335, mir-338, mir-375, mir-421, mir-484, mir-505, mir-769, mir-944, mir-1468, mir-3648, and let-7i in a sample from a patient relative to the expression level of the one or more miRNAs in a control sample; and administering an effective amount of an esophageal treatment to the diagnosed patient.

公开(公告)号：US20210308242A1

公开(公告)日：2021-10-07

申请号：US17301704

申请日：2021-04-12

Applicant: BAYLOR RESEARCH INSTITUTE

Inventor： Gerard ZURAWSKI ,  Jacques F. Banchereau ,  Anne-Laure FLAMAR ,  Peter KLUCAR ,  Keiko AKAGAWA ,  Sandra ZURAWSKI ,  SangKon OH

IPC: A61K39/00 ,  C07K16/28 ,  C07K14/435

Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.

公开(公告)号：US20210268097A1

公开(公告)日：2021-09-02

申请号：US17194779

申请日：2021-03-08

Applicant: BAYLOR RESEARCH INSTITUTE

Inventor： SangKon OH ,  Sandra ZURAWSKI ,  Gerard ZURAWSKI

IPC: A61K39/12 ,  A61K39/395 ,  C07K16/28 ,  C07K14/005 ,  C12N7/00

Abstract: Embodiments relate to novel vaccines against human papillomavirus (HPV) and HPV-related diseases, including multiple types of cancers. The HPV vaccines are composed of anti-human dendritic cell (DC) surface receptor antibodies, including CD40, and E6/7 proteins of HPV16 and 18. The technology described is not limited to making vaccines against HPV16- and HPV18-related diseases and can be applied to making vaccines carrying E6/7 from any type of HPV. The HPV vaccines described can target DCs, major and professional antigen presenting cells (APCs), and can induce and activate potent HPV E6/7-specific and strong CD4+ and CD8+ T cell responses. The HPV vaccines can be used for the prevention of HPV infection and HPV-related diseases as well as for the treatment of HPV-related diseases, including cancers.